Benzinga | May 5, 2021 08:56AM EDT

Genprex Announces Centralized Institutional Review Board Approval For Acclaim-1 Clinical Trial In Non-Small Cell Lung Cancer

Company achieves another milestone relating to its clinical trial strategy

Acclaim-1 clinical trial to treat late-stage NSCLC patients whose disease progressed on Tagrisso(r)

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company has received centralized Institutional Review Board (IRB) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer (NSCLC). Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines the Company's lead drug candidate, REQORSA(tm) immunogene therapy, with AstraZeneca's Tagrisso(r) (osimertinib) in patients with late-stage NSCLC with mutated epidermal growth factor receptors (EGFRs), whose disease progressed after treatment with Tagrisso.